Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

9.5%

2 terminated out of 21 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

38%

8 trials in Phase 3/4

Results Transparency

15%

2 of 13 completed with results

Key Signals

2 with results87% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (4)
P 1 (2)
P 2 (3)
P 3 (4)
P 4 (4)

Trial Status

Completed13
Unknown3
Terminated2
Not Yet Recruiting1
Recruiting1
Active Not Recruiting1

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07569913Not ApplicableNot Yet Recruiting

A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test

NCT07563309Not ApplicableRecruiting

A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test

NCT05117541Completed

Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

NCT04704024Phase 3Active Not RecruitingPrimary

Reducing Vertical Transmission of Hepatitis B in Africa

NCT06368479Not ApplicableCompleted

Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings

NCT06368466Not ApplicableCompleted

A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites

NCT02143401Phase 1Completed

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

NCT03887702Phase 3TerminatedPrimary

Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

NCT01970254Completed

Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy

NCT03627507Phase 2CompletedPrimary

Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.

NCT03519113Phase 2UnknownPrimary

HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

NCT03476083Phase 4UnknownPrimary

Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission

NCT01488526Phase 4CompletedPrimary

Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

NCT03865966UnknownPrimary

Hepatitis B Virus Infection After Liver Transplantation in Children

NCT02826018Phase 1Terminated

A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection

NCT02443233CompletedPrimary

Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong

NCT00489099Phase 3CompletedPrimary

A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)

NCT00841477Phase 3CompletedPrimary

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

NCT02304315Phase 2CompletedPrimary

A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients

NCT01788371Phase 4CompletedPrimary

Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus

Scroll to load more

Research Network

Activity Timeline